Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: DCE-MRI scans Clear all
Completed No phase listed Observational

Non-Invasive Imaging of Atherosclerosis

NCT01418313
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
20 Years and older
Enrollment
886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 25, 2026, 2:12 PM EDT
Withdrawn No phase listed Observational

QSM and Regional DCE MRI Permeability Using GOCART Technique

NCT03091803
View directory record Official record
Conditions
Intracranial Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadoterate Meglumine, Magnetic Resonance Imaging
Device · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 1 Interventional Results available

Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response

NCT00694096
View directory record Official record
Conditions
Renal Cell Cancer
Interventions
Sunitinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Sep 25, 2026, 2:12 PM EDT
Terminated Phase 1 Interventional

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

NCT03971734
View directory record Official record
Conditions
High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
Interventions
Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

Bevacizumab and Temsirolimus in Patients With Advanced Malignancy

NCT00610493
View directory record Official record
Conditions
Advanced Cancer
Interventions
Bevacizumab, Temsirolimus, Additional Blood Drawn, Biopsy, DCE-MRI Scan
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 25, 2026, 2:12 PM EDT
Completed No phase listed Observational

MRI Assessment of Leukemia Response to Therapy

NCT01537159
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system
Device
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
8 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Sep 25, 2026, 2:12 PM EDT
Not listed Not applicable Interventional

Development and Validation of Advanced MRI Methods for Clinical Applications

NCT03264300
View directory record Official record
Conditions
Brain Tumor
Interventions
MRI
Other
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics

NCT02144311
View directory record Official record
Conditions
Ovarian Cancer
Interventions
PET/CT Scan, MRI
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Sep 25, 2026, 2:12 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Optimization of Novel DCE-MRI Imaging Sequences for Cancer Therapy Monitoring

NCT01752231
View directory record Official record
Conditions
Normal Volunteers
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Sep 25, 2026, 2:12 PM EDT
Active, not recruiting Early Phase 1 Interventional

DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

NCT02744053
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Triple-Negative Breast Carcinoma
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Laboratory Biomarker Analysis, Scintimammography, Technetium Tc-99m Sestamibi
Procedure · Other · Radiation + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
6
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 25, 2026, 2:12 PM EDT
Terminated No phase listed Observational

Functional Imaging of Tumor and Normal Tissue

NCT00933114
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
MRI and PET imaging
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improved Breast MRI With SWIFT

NCT01156987
View directory record Official record
Conditions
Breast Cancer
Interventions
Magnetic resonance imaging
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 25, 2026, 2:12 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

NCT02623972
View directory record Official record
Conditions
Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions
Eribulin, Adriamycin, Cyclophosphamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Imaging in MGUS, SMM and MM

NCT01237054
View directory record Official record
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
18-NaF PET, DCE-MRI, 18-FDG PET/CT
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 25, 2026, 2:12 PM EDT
Completed Not applicable Interventional Results available

Staging of Axillary Lymph Nodes Using the PEM Flex Solo II Pet Scanner in Patients With Breast Cancer

NCT01011946
View directory record Official record
Conditions
Breast Cancer
Interventions
Positron Emission Mammography
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Sep 25, 2026, 2:12 PM EDT
Terminated Early Phase 1 Interventional

Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI

NCT01895829
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Magnetic Resonance Imaging (MRI), Ferumoxytol
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Sep 25, 2026, 2:12 PM EDT
Completed No phase listed Observational

Immunoscore in Rectal Cancer

NCT02017509
View directory record Official record
Conditions
Cancer of the Rectum, Neoplasms, Rectal, Rectal Cancer, Rectal Tumors, Rectal Adenocarcinoma
Interventions
Diagnostic Biopsy and Surgical Procedure, Intravoxel incoherent motion MRI (IVIM), Dynamic Contrast Enhanced MRI (DCE-MRI), RNA gene expression analysis
Procedure · Genetic
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 25, 2026, 2:12 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military

NCT04058132
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Sildenafil Citrate 50Mg Tab, functional Near-infrared Spectroscopy (fNIRS), Carbon Dioxide (CO2) 5%, Neuropsychological Assessments, Gadolinium contrast infusion, Blood sample collection for research purposes, Structural brain Magnetic Resonance Imaging (MRI
Drug · Device · Other + 1 more
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 25, 2026, 2:12 PM EDT
Terminated Phase 2 Interventional

Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer

NCT00095693
View directory record Official record
Conditions
Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage III Follicular Thyroid Cancer, Stage III Papillary Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
Interventions
sorafenib tosylate, laboratory biomarker analysis, pharmacological study, fludeoxyglucose F 18, positron emission tomography, dynamic contrast-enhanced magnetic resonance imaging
Drug · Other · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Sep 25, 2026, 2:12 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Comparison of Quantitative MRI Perfusion Methods With Quantitative PET Perfusion Imaging

NCT02608944
View directory record Official record
Conditions
MRI Scans
Interventions
Adenosine, Regadenoson, O-15 labeled radioactive water, MRI, PET Imaging
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 13, 2020 · Synced Sep 25, 2026, 2:12 PM EDT
Completed No phase listed Observational

Non-Invasive Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy Techniques (MRS) for Assessing Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

NCT00490503
View directory record Official record
Conditions
Breast Cancer
Interventions
Magnetic Resonance Imaging (MRI), Magnetic Resonance Spectroscopy (MRS)
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Sep 25, 2026, 2:12 PM EDT
Terminated Not applicable Interventional Results available

3-Tesla MRI Response to TACE in HCC (Liver Cancer)

NCT02057874
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Stage A Adult Primary Liver Cancer (BCLC), Stage B Adult Primary Liver Cancer (BCLC)
Interventions
3 Tesla Magnetic Resonance Imaging, Magnevist® (Intravenous (IV) administration of MRI contrast agent)
Device · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 25, 2026, 2:12 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

DCE MRI in Patients With Pancreatic Cancer

NCT02070705
View directory record Official record
Conditions
Familial Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 25, 2026, 2:12 PM EDT
Terminated No phase listed Observational

MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer

NCT01992861
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Cervical Undifferentiated Carcinoma, Recurrent Cervical Carcinoma, Stage IB2 Cervical Cancer, Stage II Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IVA Cervical Cancer
Interventions
Computed Tomography, Diffusion Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fludeoxyglucose F-18, Magnetic Resonance Spectroscopic Imaging, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
4
States / cities
Miami, Florida • Maywood, Illinois • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Sep 25, 2026, 2:12 PM EDT